Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension
Renato Mantegazza(Italian Association for Cancer Research), Maria da Penha Ananias Morita, Srikanth Muppidi(Stanford Health Care), David Feder, Renata Martins Ribeiro, Alzira Alves de Siqueira Carvalho(Centro Universitário Fundação Santo André), Jan Vynckier(Valve (United States)), Philip Van Damme(Universitair Ziekenhuis Leuven), Annelies Vanhee, Guy Van den Abeele, Luiz Augusto da Silva, Kathy de Koning, Nicolas Vandenbussche(Ghent University Hospital), Mariela Bettini, Caroline Schotte, Fanny O’Brien(Alexion Pharmaceuticals (United States)), Délphine Mahieu, Juliet Saba, Miguel Wilken, Bruno Bezerra Rosa, Heather Booth(Alnylam Pharmaceuticals (United States)), Thabata Veiga, James F. Howard(University of North Carolina at Chapel Hill), Kenji P. Fujita, Heinz Wiendl(University Medical Center Freiburg), Gonzalo Vidal, Fábio Barroso(Université Paris-Sud), Rudy Mercelis, Ann D’Hont(Alnylam Pharmaceuticals (United States)), Ana Paula Souto Melo(University of Washington), Charlotte Smetcoren, Sarah Verjans, Petra Tilkin, Olivier Stevens, Linda Wagemaekers, Igor Dias Brockhausen, Gil I. Wolfe(University at Buffalo, State University of New York), Alejandra Dalila Garcia, Marcelo Rugiero, Rosana Rocha, Jan De Bleecker(Ghent University Hospital), Katrien De Mey, Claudio Mazia, Annelies Depreitere, Sien Van Daele, Daniel Ambrosio, Marcelo Chaves, Murilo Santos Engel, Gabor Lovasamela César, Jordana Gonçalves Geraldo
Cited by 80
Related Papers
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
|The Lancet Neurology|2017|820
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706
Ofatumumab versus Teriflunomide in Multiple Sclerosis
|New England Journal of Medicine|2020|706
How patients with multiple sclerosis acquire disability
|Brain|2022|532